FILTER BY:
Details
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 or mNF2 Gene Mutations
Address: 450 Brookline Ave, Boston, MA 02215, USA
Phone: 877-451-7009
Mesothelioma Type:
- Pleural: True
- Peritoneal: True
- Pericardial: True
- Tunica Vaginalis: True
Type: Epitheliod, Sarcomatoid, Biphasic
Condition: Solid Tumor - Adult, Mesothelioma
Description: This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered once daily in 3- or 4-week cycles in patients with mesothelioma and/or metastatic solid tumors that are resistant or refractory to standard therapy or for which no effective standard therapy is available.
Research Center: Dana-Farber Cancer Institute
Treatment Interventions: DRUG: VT3989
Potential Impact: Fake Data
Clinical Trial Number: NCT04665206
Phase: Phase 2, Phase 1
Status: Recruiting
